News
Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...
The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...
2h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
President Donald Trump told Fox News host Sean Hannity that the pal who starred in the "fat shot" story was "very worried" ...
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Explore more
WEDNESDAY, May 14, 2025 (HealthDay News) — More U.S. teenagers are getting weight-loss surgery, despite the discovery of new ...
Studies have shown that GLP-1s reduce inflammation in the brain and regulate anxiety as well as depression. When insurance ...
People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...
Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results